Neurocrine Biosciences
NBIX
#1622
Rank
NZ$21.97 B
Marketcap
NZ$218.92
Share price
-0.02%
Change (1 day)
12.45%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2024: NZ$1.03 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are NZ$2.68 Billion. In 2024 the company made an earning of NZ$1.03 Billion, an increase over its 2023 earnings that were of NZ$0.52 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2024

Annual earnings

Year Earnings Change
2024NZ$1.03 B96.41%
2023NZ$0.52 B41.13%
2022NZ$0.37 B73.74%
2021NZ$0.21 B-8.82%
2020NZ$0.23 B77.78%
2019NZ$0.13 B49.83%
2018NZ$88.3 M-142.57%
2017-NZ$0.21 Billion-14.73%
2016-NZ$0.25 Billion53.15%
2015-NZ$0.16 Billion46.25%
2014-NZ$0.11 Billion29.66%
2013-NZ$83.77 Million-3530.8%
2012NZ$2.44 M-95.73%
2011NZ$57.19 M
2009-NZ$80.41 Million-45.38%
2008-NZ$0.15 Billion-58.87%
2007-NZ$0.36 Billion87.3%
2006-NZ$0.2 Billion351.97%
2005-NZ$42.28 Million-52.09%
2004-NZ$88.25 Million-10.98%
2003-NZ$99.13 Million
2001-NZ$73.99 Million
1999-NZ$33.37 Million108.32%
1998-NZ$16.02 Million
1996NZ$4.88 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$19.98 B 1,932.24%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$2.79 B 184.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$37.94 B 3,758.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$44.07 M-95.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-NZ$70.42 Million-107.16%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$85.23 M-91.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-NZ$8.09 Million-100.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.66 B 171.24%๐Ÿ‡ฌ๐Ÿ‡ง UK